



Final Appraisal Recommendation

Advice No: 1719 – November 2019

**Diamorphine hydrochloride (Ayendi®)
720 microgram/actuation and 1600 microgram/actuation
Nasal Spray**

Limited submission by Wockhardt UK Ltd

Recommendation of AWMSG

Diamorphine hydrochloride (Ayendi®) is recommended as an option for use within NHS Wales for the treatment of acute severe nociceptive pain in children and adolescents 2 to 15 years of age in a hospital setting. Ayendi® nasal spray should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with the appropriate monitoring.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2406), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1719:
Diamorphine hydrochloride (Ayendi®) 720 microgram/actuation and 1600 microgram/actuation Nasal Spray. November 2019.